Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 278

Results For "ED"

9539 News Found

Lupin launches posaconazole delayed-release tablets
News | February 18, 2021

Lupin launches posaconazole delayed-release tablets

posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.


Approval accorded under PLI Scheme for domestic manufacturing of medical devices
News | February 12, 2021

Approval accorded under PLI Scheme for domestic manufacturing of medical devices

The medical device Sector in India suffers from a considerable cost of manufacturing disability.


LupinLife Launches ayurvedic energy supplement
News | February 12, 2021

LupinLife Launches ayurvedic energy supplement

Be One is a 100% Ayurvedic health and wellness supplement.


SMS Pharmaceuticals Q3FY21 consolidated PAT up to Rs. 21.39 Cr
News | February 11, 2021

SMS Pharmaceuticals Q3FY21 consolidated PAT up to Rs. 21.39 Cr

The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.


Sun Pharma Advanced Research Q3FY21 loss at Rs. 67.62 crore
News | February 11, 2021

Sun Pharma Advanced Research Q3FY21 loss at Rs. 67.62 crore

The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.


J B Chemicals & Pharmaceuticals Q3FY 21 consolidated PAT up at Rs. 151.66 Cr
News | February 11, 2021

J B Chemicals & Pharmaceuticals Q3FY 21 consolidated PAT up at Rs. 151.66 Cr

The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.


Jubilant Pharmova Q3FY21 consolidated PAT at Rs. 309.93 Cr
News | February 08, 2021

Jubilant Pharmova Q3FY21 consolidated PAT at Rs. 309.93 Cr

The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.


Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr
News | February 06, 2021

Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr

The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.


GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr
News | February 06, 2021

GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr

The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.


Dr. Reddy's Laboratories reports Rs. 19.8 Cr PAT in Q3FY21
News | February 01, 2021

Dr. Reddy's Laboratories reports Rs. 19.8 Cr PAT in Q3FY21

The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.